Table 1.
Publication Year | Author | N | AVR Type | Design | 1-Year HF Hospitalization |
---|---|---|---|---|---|
2022 | Huded et al. [14] | 3403 | SAVR and TAVR | Secondary analysis of RCTs | 6.7% |
2020 | Auffret et al. [30] | 808 | TAVR | Single-center retrospective | 13.6% |
2019 | Vemulapalli et al. [26] | 15,324 | TAVR | Multicenter retrospective | 14.2% |
2019 | Guedeney et al. [16] | 1139 | TAVR | Multicenter prospective | 9.2% |
2019 | Harbaoui et al. [24] | 409 | TAVR | Multicenter prospective | 19.9% |
2018 | Nazzari et al. [25] | 742 | TAVR | Multicenter prospective | 12.4% |
2017 | Durand et al. [23] | 546 | TAVR | Single-center retrospective | 24.1% |
2017 | Forcillo et al. [31] | 714 | TAVR | Single-center retrospective | 7.6% |
2015 | Holmes Jr et al. [18] | 12,182 | TAVR | Multicenter retrospective | 14.3% |
AVR = aortic valve replacement. HF = heart failure. RCT = randomized controlled trial. SAVR = surgical aortic valve replacement. TAVR = transcatheter aortic valve replacement.